Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers. (PubMed, Cancer Treat Res Commun) - Oct 15, 2026 - "These approaches expand therapeutic options for melanoma, but randomized evidence of improved outcomes is available only for some. HLA restriction, treatment burden, and manufacturing complexity remain key challenges, and ongoing phase III trials will define their clinical role."
Checkpoint inhibition • Journal • Review • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • HLA-A • PRAME
|
|
Alessandra Gennari; Alice Gatti; Andrea Boutros; Andrea Sponghini; Elia Esposto; Elisa Zavattaro; Francesca Zottarelli; Ida Taglialatela; Leonardo Di Corcia; Pamela Farinelli; Paola Savoia; Roberto Giorgione
|